Most Pioneering Vaccine Development Company 2019 & GHP Award for Innovation in Vaccine Immunology
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines based on its proprietary oral delivery platform. Vaxart’s vaccines are designed to generate broad, durable immune responses that protect against a wide range of infectious diseases and may also be useful for the treatment of chronic viral infections and cancer. Vaxart’s vaccines are administered using a convenient room temperature-stable tablet, which Vaxart believes allows easier distribution and administration compared to injectable vaccines and has the potential to significantly increase vaccination rates. Vaxart’s pipeline includes prophylactic vaccines for norovirus, seasonal influenza, and RSV, along with a therapeutic HPV vaccine.